Expert Opinion on Biological Therapy

Papers
(The H4-Index of Expert Opinion on Biological Therapy is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli76
Biosimilars and access to biologic therapy in immune-mediated diseases59
Management of chronic recurrent multifocal osteomyelitis: review and update on the treatment protocol58
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males54
The endosomal-lysosomal system in ADC design and cancer therapy53
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases43
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions41
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?32
Aflibercept biosimilars – so near, yet so far32
IL-4/IL-13 targeted biologics in atopic dermatitis: is their use safe in oncologic patients?31
Antibody drug conjugates for glioblastoma: current progress towards clinical use31
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era28
Bispecific antibody combination regimens for B-cell non-Hodgkin’s lymphomas28
Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences28
Signaling new therapeutic opportunities: cytokines in prostate cancer27
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway26
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden26
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)26
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma25
Correction25
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?24
Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials23
Long-acting delivery and therapies for neovascular age-related macular degeneration23
0.11424899101257